156 related articles for article (PubMed ID: 33502174)
1. Preclinical Evaluation of an
Tago T; Toyohara J; Ishii K
ACS Chem Neurosci; 2021 Feb; 12(4):746-755. PubMed ID: 33502174
[TBL] [Abstract][Full Text] [Related]
2. Radiosynthesis and preliminary evaluation of an
Tago T; Toyohara J; Ishii K
J Labelled Comp Radiopharm; 2020 Feb; 63(2):85-95. PubMed ID: 31881107
[TBL] [Abstract][Full Text] [Related]
3. Preclinical validation of a novel brain-penetrant PET ligand for visualization of histone deacetylase 6: a potential imaging target for neurodegenerative diseases.
Tago T; Sakata M; Kanazawa M; Yamamoto S; Ishii K; Toyohara J
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2193-2203. PubMed ID: 38441662
[TBL] [Abstract][Full Text] [Related]
4. Translation of HDAC6 PET Imaging Using [
Celen S; Rokka J; Gilbert TM; Koole M; Vermeulen I; Serdons K; Schroeder FA; Wagner FF; Bleeser T; Hightower BG; Hu J; Rahal D; Beyzavi H; Vanduffel W; Van Laere K; Kranz JE; Hooker JM; Bormans G; Cawthorne CJ
ACS Chem Neurosci; 2020 Apr; 11(7):1093-1101. PubMed ID: 32159328
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
Jian W; Wei X; Chen L; Wang Z; Sun Y; Zhu S; Lou H; Yan S; Li X; Zhou J; Zhang B
Neurosci Lett; 2017 Sep; 658():114-120. PubMed ID: 28823893
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Shen S; Picci C; Ustinova K; Benoy V; Kutil Z; Zhang G; Tavares MT; Pavlíček J; Zimprich CA; Robers MB; Van Den Bosch L; Bařinka C; Langley B; Kozikowski AP
J Med Chem; 2021 Apr; 64(8):4810-4840. PubMed ID: 33830764
[TBL] [Abstract][Full Text] [Related]
9. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
Zhang L; Liu C; Wu J; Tao JJ; Sui XL; Yao ZG; Xu YF; Huang L; Zhu H; Sheng SL; Qin C
J Alzheimers Dis; 2014; 41(4):1193-205. PubMed ID: 24844691
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
11. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
12. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
13. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
[TBL] [Abstract][Full Text] [Related]
14. Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.
Kozikowski AP; Shen S; Pardo M; Tavares MT; Szarics D; Benoy V; Zimprich CA; Kutil Z; Zhang G; Bařinka C; Robers MB; Van Den Bosch L; Eubanks JH; Jope RS
ACS Chem Neurosci; 2019 Mar; 10(3):1679-1695. PubMed ID: 30511829
[TBL] [Abstract][Full Text] [Related]
15. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
Jochems J; Boulden J; Lee BG; Blendy JA; Jarpe M; Mazitschek R; Van Duzer JH; Jones S; Berton O
Neuropsychopharmacology; 2014 Jan; 39(2):389-400. PubMed ID: 23954848
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.
Leyk J; Goldbaum O; Noack M; Richter-Landsberg C
J Mol Neurosci; 2015 Apr; 55(4):1031-46. PubMed ID: 25434725
[TBL] [Abstract][Full Text] [Related]
18. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
19. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
20. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
